Erste Group Bank Predicts Gilead Sciences FY2027 Earnings

Gilead Sciences, Inc. (NASDAQ:GILD) – Equities research analysts at Erste Group Bank boosted their FY2027 earnings per share (EPS) estimates for Gilead Sciences in a report issued on Thursday, June 25th. Erste Group Bank analyst H. Engel now forecasts that the biopharmaceutical company will post earnings of $9.66 per share for the year, up from their prior forecast of $9.65. The consensus estimate for Gilead Sciences’ current full-year earnings is ($0.80) per share.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. During the same period in the prior year, the company posted $1.81 EPS. The business’s quarterly revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS.

Several other equities research analysts have also commented on the company. Morgan Stanley cut their price objective on Gilead Sciences from $175.00 to $168.00 in a research note on Friday, May 8th. Weiss Ratings downgraded Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, May 28th. Citigroup lifted their price target on Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. The Goldman Sachs Group boosted their price target on Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a research report on Friday, April 17th. Finally, Royal Bank Of Canada restated a “sector perform” rating on shares of Gilead Sciences in a report on Monday, June 8th. Twenty-five research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $158.41.

Gilead Sciences Stock Up 0.0%

GILD stock opened at $126.34 on Wednesday. The stock has a market capitalization of $156.86 billion, a P/E ratio of 17.21 and a beta of 0.31. Gilead Sciences has a 52 week low of $107.75 and a 52 week high of $157.29. The firm has a 50-day simple moving average of $129.72 and a 200-day simple moving average of $134.46. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, June 29th. Shareholders of record on Monday, June 15th were paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend was Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is 44.69%.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $125.40, for a total transaction of $376,200.00. Following the transaction, the chief financial officer directly owned 171,646 shares in the company, valued at $21,524,408.40. The trade was a 1.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $131.29, for a total value of $3,676,120.00. Following the completion of the sale, the insider owned 125,779 shares of the company’s stock, valued at $16,513,524.91. This trade represents a 18.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 68,000 shares of company stock worth $8,930,150 in the last ninety days. Insiders own 0.30% of the company’s stock.

Institutional Trading of Gilead Sciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. Strategic Investment Solutions Inc. IL acquired a new stake in Gilead Sciences during the fourth quarter worth about $25,000. Vermillion & White Wealth Management Group LLC grew its stake in shares of Gilead Sciences by 71.4% in the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 85 shares during the period. Quattro Advisors LLC purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $26,000. Wealth Preservation Advisors LLC increased its holdings in shares of Gilead Sciences by 60.0% during the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 81 shares during the last quarter. Finally, Ares Financial Consulting LLC acquired a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $28,000. 83.67% of the stock is owned by institutional investors and hedge funds.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.